For research use only. Not for therapeutic Use.
Rottlerin（Cat No.:I009189）is a selective inhibitor of protein kinase Cδ (PKCδ), a member of the protein kinase C family that plays a critical role in various cellular processes, including apoptosis, cell proliferation, and differentiation. By targeting PKCδ, rottlerin modulates signaling pathways associated with cancer progression and inflammation. This compound has demonstrated potential anti-tumor effects in preclinical studies, particularly in hematologic malignancies and solid tumors. Rottlerin’s unique mechanism of action makes it a valuable tool for investigating the role of PKCδ in disease processes and for exploring new therapeutic strategies in cancer treatment.
| Catalog Number | I009189 |
| CAS Number | 82-08-6 |
| Synonyms | Rottlerin; Kamalin; Mallotoxin; NSC 56346; NSC 94525.;(E)-1-(6-((3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl)-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl)-3-phenyl-2-propen-1-one |
| Molecular Formula | C30H28O8 |
| Purity | ≥95% |
| Target | PKC |
| Solubility | Soluble in DMSO |
| Storage | 2-8°C |
| IUPAC Name | (E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one |
| InChI | InChI=1S/C30H28O8/c1-15-24(33)19(27(36)22(16(2)31)25(15)34)14-20-26(35)18-12-13-30(3,4)38-29(18)23(28(20)37)21(32)11-10-17-8-6-5-7-9-17/h5-13,33-37H,14H2,1-4H3/b11-10+ |
| InChIKey | DEZFNHCVIZBHBI-ZHACJKMWSA-N |
| SMILES | CC1=C(C(=C(C(=C1O)C(=O)C)O)CC2=C(C(=C3C(=C2O)C=CC(O3)(C)C)C(=O)/C=C/C4=CC=CC=C4)O)O |
| Reference | </br>1:Rottlerin-mediated inhibition of Toxoplasma gondii growth in BeWo trophoblast-like cells. Ietta F, Maioli E, Daveri E, Gonzaga Oliveira J, da Silva RJ, Romagnoli R, Cresti L, Maria Avanzati A, Paulesu L, Barbosa BF, Gomes AO, Roberto Mineo J, Ferro EAV.Sci Rep. 2017 Apr 28;7(1):1279. doi: 10.1038/s41598-017-01525-6. PMID: 28455500 Free PMC Article</br>2:Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma. Zhu Y, Wang M, Zhao X, Zhang L, Wu Y, Wang B, Hu W.Oncotarget. 2017 Apr 4;8(14):22825-22834. doi: 10.18632/oncotarget.15221. PMID: 28423559 Free PMC Article</br>3:Synergism between PKCδ regulators hypericin and rottlerin enhances apoptosis in U87 MG glioma cells after light stimulation. Misuth M, Horvath D, Miskovsky P, Huntosova V.Photodiagnosis Photodyn Ther. 2017 Mar 31. pii: S1572-1000(16)30266-6. doi: 10.1016/j.pdpdt.2017.03.018. [Epub ahead of print] PMID: 28373118 </br>4:Rottlerin-induced autophagy leads to apoptosis in bladder cancer cells. Qi P, He Z, Zhang L, Fan Y, Wang Z.Oncol Lett. 2016 Dec;12(6):4577-4583. doi: 10.3892/ol.2016.5255. Epub 2016 Oct 13. PMID: 28101215 Free PMC Article</br>5:Rottlerin exhibits antitumor activity via down-regulation of TAZ in non-small cell lung cancer. Zhao Z, Zheng N, Wang L, Hou Y, Zhou X, Wang Z.Oncotarget. 2017 Jan 31;8(5):7827-7838. doi: 10.18632/oncotarget.13974. PMID: 27999199 Free PMC Article</br>6:The Natural Plant Product Rottlerin Activates Kv7.1/KCNE1 Channels. Matschke V, Piccini I, Schubert J, Wrobel E, Lang F, Matschke J, Amedonu E, Meuth SG, Strünker T, Strutz-Seebohm N, Greber B, Scherkenbeck J, Seebohm G.Cell Physiol Biochem. 2016;40(6):1549-1558. doi: 10.1159/000453205. Epub 2016 Dec 21. PMID: 27997884 Free Article</br>7:Stimulation of Suicidal Erythrocyte Death by Rottlerin. Mischitelli M, Jemaà M, Almasry M, Faggio C, Lang F.Cell Physiol Biochem. 2016;40(3-4):558-566. Epub 2016 Nov 25. PMID: 27889758 Free Article</br>8:Rottlerin exhibits anti-cancer effect through inactivation of S phase kinase-associated protein 2 in pancreatic cancer cells. Su J, Wang L, Yin X, Zhao Z, Hou Y, Ye X, Zhou X, Wang Z.Am J Cancer Res. 2016 Oct 1;6(10):2178-2191. eCollection 2016. PMID: 27822410 Free PMC Article</br>9:Rottlerin inhibits cell growth and invasion via down-regulation of Cdc20 in glioma cells. Wang L, Hou Y, Yin X, Su J, Zhao Z, Ye X, Zhou X, Zhou L, Wang Z.Oncotarget. 2016 Oct 25;7(43):69770-69782. doi: 10.18632/oncotarget.11974. PMID: 27626499 Free PMC Article</br>10:Rottlerin exerts its anti-tumor activity through inhibition of Skp2 in breast cancer cells. Yin X, Zhang Y, Su J, Hou Y, Wang L, Ye X, Zhao Z, Zhou X, Li Y, Wang Z.Oncotarget. 2016 Oct 11;7(41):66512-66524. doi: 10.18632/oncotarget.11614. PMID: 27582552 Free PMC Article |
